NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION FOR LOCALLY ADVANCED HEAD AND NECK CANCERS

Weekly cisplatin (40 mg/m2) versus three-weekly (100mg/m2) cisplatin delivered concurrently with radiotherapy in high risk head and neck cancer patients

Weekly versus every three weeks cisplatin as concurrent chemoradiotherapy in locally advanced head and neck cancer: single institution experience

Induction Chemotherapy Followed by Concurrent Chemoradiation versus Concurrent Chemoradiation alone For Locally Advanced Laryngeal & Nasopharyngeal Cancers: A Retrospective Study

COMPARISON BETWEEN CONCOMITANT CHEMO-RADIOTHERAPY WITH CISPLATIN VERSUS INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY WITH CISPLATIN AND ETOPOSIDE REGIMEN IN C

Optimizing a Convenient Protocol in Induction Treatment Of Locally Advanced Head And Neck Cancers: Taxotere- Cisplatin- 5 Fluorouracil versus Cisplatin-5 Fluorouracil

Gemcitabine vs cisplatin concurrent with radiation therapy in locally advanced squamous cell carcinoma of head and neck cancer

Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma

Evaluation of Concurrent Adjuvant Chemotherapy Paclitaxel and Radiotherapy in Breast Conserving Management of Early Breast Cancer

Induction Chemotherapy Versus Upfront Chemoradiation for Locoregionally Advanced of Head and Neck Cancer